'PDS Biotech's Survival Benefit Is Absurdly Overstated' - By Adam Feuerstein/ STAT News
'PDS Biotech's Survival Benefit Is Absurdly Overstated' - By Adam Feuerstein/ STAT News
This is the online edition of Adam's Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
這是Adam's Biotech Scorecard的在線版本，這是一份新的僅限訂閱者的時事通訊。STAT+ 訂閱者可以註冊 這裏 以便每週四將其發送到他們的收件箱。
Hello, friends! I'm in San Francisco for the STAT Breakthrough Summit. Later today, I'll be "fireside chatting" with Cytokinetics CEO Robert Blum. It's not too late to join us virtually. Check out details here.
你好，朋友們！我在舊金山參加 STAT 突破峯會。今天晚些時候，我將與Cytokinetics首席執行官羅伯特·布魯姆 “爐邊聊一聊”。現在虛擬加入我們還爲時不晚。在此處查看詳細信息。
It's a travel-shortened week for me, so in this newsletter, I decided to dive deep into PDS Biotech and its experimental drug for head and neck cancer. PDS is what I'd call a biotech cult stock.
對我來說，這周的旅行時間縮短了，所以在這份時事通訊中，我決定深入研究PDS Biotech及其治療頭頸癌的實驗藥物。PDS就是我所說的生物技術狂熱股票。
STAT+ EXCLUSIVE STORY
STAT+ 獨家故事
Already have an account? Log in
已經有賬號了嗎？登錄
譯文內容由第三人軟體翻譯。